BioSpace News Archive

The regulator Wednesday approved expanding Lonsurf’s label for previously treated metastatic colorectal cancer, authorizing a combination regimen with Roche’s bevacizumab.

The biotech Thursday reported that second-quarter sales of its COVID shot dropped 94%. However, it expects $6 billion to $8 billion in revenue this year, up from a previous forecast of $5 billion.

During Regeneron’s second-quarter earnings call Thursday, the company said that the regulator could make its decision on 8-mg Eylea in the third quarter—much earlier than market expectations.

Savings from just four of 10 drugs covered by the Inflation Reduction Act’s Drug Negotiation Program could reach $1.8 billion during the first year of implementation, according to research.

Roche announced the expansion of their Global Business Partnership Agreement with Sysmex.

Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has placed a new order valued at USD 120 million, primarily covering the manufacturing of new bulk product for the Company’s smallpox/mpox vaccine.

Scientists at the Research Center for Materials Nanoarchitectonics have developed micrometer-sized “liquid marbles” that can encapsulate single to several living cells, thereby aiding single-cell studies.

Kyverna Therapeutics announced the close of an oversubscribed $60 million Series B financing round extension, bringing the total Series B financing round to $145 million.

Complement Therapeutics GmbH, a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, announced the appointment of Dr Parisa Zamiri as its Chief Medical Officer, effective immediately.

Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, reported its financial results for the second quarter ended June 30, 2023 and provided a business update.